,i  #aaith ,,congress  #ast ,session    
,h4 ,r4 #dghj  ,,in ,,the ,,house ,,of  
,,representatives  ,july #bi1 #bjbe,mr4 
,arrington 7for himself1 ,mr4 ,buchanan1
 ,mr4 ,fleischmann1 ,ms4 ,tenney1 and   
,mr4 ,murphy7 introduced the following  
bill2 which was referred to the         
,committee on ,ways and ,means  ,a      
,,bill  ,to identify and take action    
against international trade practices of
 high income countries that unfairly    
exploit innovation by deviating from    
market-based policies and unfairly      
exploit ,united ,states innovation1 and 
for other purposes4  #a4 ,short title   
,this ,act may be cited as the ,use     
,sovereignty ,to reduce ,rx ,act or the 
,u,s,t,rx ,act4  #b4 ,findings2 sense of
 ,congress  7a7 ,findings ,congress     
finds the following3  7#a7              
,pharmaceutical price controls in       
foreign markets distort global trade    
flows and competition by depressing the 
prices of innovative drugs and          
exploiting pharmaceutical innovations   

researched and developed in the ,united 
,states4  7#b7 ,by setting prices at    
levels that are not market-based1 such  
price controls undervalue the discovery 
of new1 innovative treatments1 diminish 
opportunities and incentives for global 
innovation in new medicines1 and        
threaten to restrict access to new      
treatments and cures for ,united ,states
 patients and consumers4  7#c7          
,recognizing these dynamics1 it is      
critical that the ,united ,states use   
all available trade tools to address    
such free-riding to ensure that foreign 
government regulatory reimbursement     
regimes are transparent1 provide        
procedural fairness1 are                
non-discriminatory1 and provide full    
market access to ,united ,states        
products4  7b7 ,sense of ,congress ,it  
is the sense of ,congress that--  7#a7  
ensuring the security of innovative and 
affordable healthcare is a top priority 
for ,americans and for ,congress2  7#b7 
foreign government policies that mandate

 artificially low drug prices in foreign
 markets undermine this priority by     
reducing global incentives to invest in 
the development of new medicines2  7#c7 
such exploitative behavior unfairly     
shifts the cost of developing new       
treatments to the ,united ,states and   
unduly relies on ,america's patients and
 taxpayers to finance global            
pharmaceutical innovation2 and  7#d7    
safeguarding access to life-saving      
treatments for ,american patients       
requires combating such behavior so that
 foreign countries pay their fair share 
of the costs associated with the        
development of new drugs4  #c4 ,chief   
,pharmaceutical ,trade ,negotiator  7a7 
,establishment ,section #ada7;b7 of the 
,trade ,act of #aigd 7#ai ,u4,s4,c4     
#baga7;b771 is amended as follows3 7#a7 
,in paragraph 7#b7--  7,a7 in the first 
sentence1 by inserting one ,chief       
,pharmaceutical ,trade ,negotiator1     
after one ,chief ,agricultural          
,negotiator12 and  7,b7 by inserting the

 ,chief ,pharmaceutical ,trade          
,negotiator1 after the ,chief           
,agricultural ,negotiator1 each place it
 appears4  7#b7 ,by adding at the end   
the following new paragraph3  7#g7 ,the 
principal functions of the ,chief       
,pharmaceutical ,trade ,negotiator shall
 be to conduct trade negotiations1      
enforce trade agreements relating to    
,united ,states pharmaceutical products1
 and take appropriate action to address 
acts1 policies1 or practices of         
high-income countries that have a       
significant adverse impact on the       
ability of ,united ,states              
pharmaceutical manufacturers to enjoy   
full market access4 ,the ,chief         
,pharmaceutical ,trade ,negotiator shall
 be a vigorous advocate on behalf of    
,united ,states manufacturers and       
consumers of pharmaceutical products and
 shall perform such other functions as  
the ,united ,states ,trade              
,representative may direct4 ,in carrying
 out such duties1 the ,chief            

,pharmaceutical ,negotiator shall1 as   
appropriate1 consult or coordinate with 
the ,chief ,intellectual ,property      
,negotiator4  4  7b7 ,annual report     
7#a7 ,list of high-income countries ,the
 ,united ,states ,trade ,representative 
shall compile and annually update a list
 of each foreign country that is defined
 as high-income by the official         
statistics of the ,international ,bank  
for ,reconstruction and ,development of 
the ,world ,bank4  7#b7 ,report required
 ,with respect to each country included 
on the most recent list required under  
paragraph 7#a71 the ,united ,states     
,trade ,representative1 acting through  
the ,chief ,pharmaceutical ,trade       
,negotiator1 7as established pursuant to
 the amendments made by subsection 7a77 
shall annually submit to the ,committee 
on ,ways and ,means of the ,house of    
,representatives and the ,committee on  
,finance of the ,senate and concurrently
 publish on a publicly available website
 of the ,united ,states ,trade          

,representative a report that--  7,a7   
describes in detail the results of a    
review of the acts1 policies1 and       
practices of such country relating to   
the trade in pharmaceutical products in 
the previous fiscal year2  7,b7         
determines whether such acts1 policies1 
or practices--  7i7 are not developed   
and implemented in a fair1              
nondiscriminatory1 and transparent      
manner2  7ii7 are not market-based or do
 not appropriately recognize the value  
of innovative medicines2  7iii7 deny    
reciprocal market access for ,united    
,states products2  7iv7 diminish        
incentives for innovation in a manner   
that delays1 prevents1 or otherwise     
adversely impacts the introduction of   
new medicines in the ,united ,states2   
7v7 violate or are inconsistent with the
 provisions of1 or otherwise deny       
benefits to the ,united ,states under1  
any bilateral or multilateral trade     
agreement with such country2 and  7vi7  
are unjustifiable or impose a           

significant burden or unreasonable or   
discriminatory restriction on ,united   
,states commerce with such country2 and 
7,c7 describes the current status of any
 responsive actions taken by the ,united
 ,states with respect to acts1 policies1
 or practices for which the ,united     
,states ,trade ,representative has      
determined and included in any prior    
report1 pursuant to subparagraph 7,b71  
that the interests of the ,united       
,states are harmed1 including responsive
 actions pursuant to title ,,iii of the 
,trade ,act of #aigd 7#ai ,u4,s4,c4     
#bdaa et seq474  7c7 ,response to       
adverse actions ,not later than #cj days
 after the ,united ,states ,trade       
,representative determines that an act1 
policy1 or practice of a country        
included in the applicable list required
 under subsection 7b77#a7 meets any of  
the criteria described in subsection    
7b77#b77;,b71 the ,united ,states ,trade
 ,representative shall submit to        
,committee on ,ways and ,means of the   

,house of ,representatives and the      
,committee on ,finance of the ,senate a 
plan to respond to such adverse action1 
which may include initiating an         
investigation under chapter #a title    
,,iii of the ,trade ,act of #aigd 7#ai  
,u4,s4,c4 #bdaa et seq471 in accordance 
with section #cjb7;b77#a7 of such       
chapter4